STOCK TITAN

Alx Oncology Holdings Inc - ALXO STOCK NEWS

Welcome to our dedicated news page for Alx Oncology Holdings (Ticker: ALXO), a resource for investors and traders seeking the latest updates and insights on Alx Oncology Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alx Oncology Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alx Oncology Holdings's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.26%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.38%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
management
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.87%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.62%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
management
Alx Oncology Holdings Inc

Nasdaq:ALXO

ALXO Rankings

ALXO Stock Data

726.70M
22.30M
2.67%
97.6%
6.22%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
South San Francisco

About ALXO

alx oncology (previously alexo therapeutics) is a clinical-stage immuno-oncology company developing therapies that block the cd47 myeloid checkpoint mechanism exploited by cancer cells to evade the immune system. our lead candidate, alx148, is a fusion protein that comprises an engineered high affinity cd47 binding domain of sirpa linked to an inactive fc region of human immunoglobulin. alx148 is currently being investigated in a phase 1 study in combination with checkpoint inhibitors and targeted anti-cancer antibodies (nct03013218). for more information about the company, please visit our website at www.alxoncology.com